ASU researchers have identified new methods and compositions
to directly target therapeutics to tumors while also performing diagnostic
imaging. Ultrasound contrast agent materials are combined with
glycopeptide-based antibiotics in a unique formulation capable of simultaneous
targeting of therapeutics and selective imaging.
Traditionally used with ultrasound technology for in-vivo
imaging, microbubbles typically consist of a shell comprised of albumin,
galactose or lipids enclosing a gas core. Microbubbles are administrated
intravenously to the systemic circulation, their echogenocity allows
contrast-enhanced ultrasound and improved medical sonography. In medical
imaging, these agents have applications in radiology and cardiology.
By utilizing a new and novel combination of antibiotic
therapeutic and attachment chemistries, ASU researchers have created a range of
new materials useful for drug delivery to tumor sites, while offering the
capability for selective in-vivo imaging and therapy monitoring. Appropriate
selection of microbubble functionalization enables targeting of the delivery
agent, therapy delivery and treatment monitoring. Chemistries can be selected to
enable one, or a combination of these functions.
Although the current focus is on existing clinical
therapeutics for use in treating malignant cancer cells, the platform offers
significant flexibility in type and number of therapeutic agents, and attachment
methodologies for various diagnostic and therapeutic applications.
Potential Applications
- Cancer-therapeutics
- Drug-delivery
- Therapeutic monitoring
- Tissue Imaging
Benefits and Advantages
- Ease of use - Does not use radionuclides
- Builds on well-established technologies for tissue
imaging
- Flexibility platform for expansion of therapeutic /
diagnostic application
Download original PDF
For more information about the inventor(s) and their
research, please see
Dr. Hecht's
departmental webpage
